<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03532893</url>
  </required_header>
  <id_info>
    <org_study_id>2017YFC1309500-1</org_study_id>
    <nct_id>NCT03532893</nct_id>
  </id_info>
  <brief_title>Predictive Value of Inflammatory Biomarkers and FEV1 for COPD</brief_title>
  <acronym>PIFCOPD</acronym>
  <official_title>Predictive Value of Combining Inflammatory Biomarkers and Rapid Decline of FEV1 for COPD in Chinese Population - a Prospective Cohort Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Peking University First Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>The Second Hospital of Hebei Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Henan Provincial Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Second Hospital of Jilin University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>First Affiliated Hospital Xi'an Jiaotong University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Shandong Provincial Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Shanxi Dayi Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Tianjin Medical University General Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Affiliated Hospital of Inner Mongolia Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The First Hospital of Qinhuangdao</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Peking University First Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multi-center, prospective, cohort study. A total of 10,000 people aged 40～75
      without lung disease will be recruited and followed for 3 years. By measure the rate of
      decline in forced expiratory volume at one second（FEV1） and baseline inflammatory biomarkers
      in exhaled breath condensate and peripheral blood, we aim to explore the predictive model for
      chronic obstructive pulmonary disease（COPD） in China.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a multi-center, prospective, cohort study. A total of 10,000 subjects aged 40～75
      without history of lung disease will be recruited and followed for 3 years. The Department of
      Respiratory and Critical Care of Peking University First Hospital is responsible for this
      research. Other 9 units participating in the study, include the The Second Hospital of Hebei
      Medical University, Henan Provincial People's Hospital, The Second Hospital of Jilin
      University, The First Affiliated Hospital of Xi'an Jiaotong University, Shandong Provincial
      Hospital Affiliated to Shandong University,Shanxi Dayi Hospital, Tianjin Medical University
      General Hospital, The Affiliated Hospital of Inner Mongolia Medical University,The First
      Hospital of Qinhuangdao. Some questionnaire such as St George's Respiratory Questionnaire
      (SGRQ), income class, educational level, comorbidity, smoking habit and biomass smoke
      exposure history will be collected. The baseline level of Interleukin 6 (IL-6),
      high-sensitivity C-reactive Protein (hs-CRP), microRNAs-23a (miR-23a) in peripheral blood and
      pH value in exhaled breath condensate (EBC) will be measured, lung spirometry will be tested
      in the first, second and fourth years. Primary outcome is the incidence of COPD, multivariate
      regression analysis will be used to establish the predictive model for COPD in China.

      The study protocol has been approved by the Peking University First Hospital Institutional
      Review Board (IRB) (2018-31). Any protocol modifications will be submitted for the IRB review
      and approval.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 4, 2018</start_date>
  <completion_date type="Anticipated">June 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>The incidence of COPD in the second and fourth year and the association between incidence of COPD and rapid decline of FEV1.</measure>
    <time_frame>4 years</time_frame>
    <description>FEV1/FVC(forced vital capacity)&lt;70% (after bronchial dilation test);Detect the decline of FEV1(%)by Vitalograph COPD6.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The association between incidence of COPD and the air pollution level in different provinces in China.</measure>
    <time_frame>4 years</time_frame>
    <description>Record data of air pollution in different provinces in China from the environmental monitoring website. And analyze the correlation between the COPD incidence and air pollution level.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The association between incidence of COPD and different comorbidity condition, such as metabolic syndrome, cardiovascular disease.</measure>
    <time_frame>4 years</time_frame>
    <description>Record comorbidity condition data of human subjects, and then analyze the correlation between the COPD incidence and different comorbidity condition.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The mean decline rate of FEV1</measure>
    <time_frame>4 years</time_frame>
    <description>Monitor pulmonary function decline in the second and the fourth year, then calculate the mean decline value.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The association between decline rate of FEV1 and air pollution level</measure>
    <time_frame>4 years</time_frame>
    <description>Record data of air pollution in different provinces in China from the environmental monitoring website. And analyze the correlation between the decline rate of FEV1 and air pollution level.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The correlation between the incidence of COPD and serum IL-6 level.</measure>
    <time_frame>4 years</time_frame>
    <description>Detect the serum IL-6 levels(ng/L), then analyze the correlation between the IL-6 levels and COPD incidence.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The correlation between the incidence of COPD and serum hs-CRP level.</measure>
    <time_frame>4 years</time_frame>
    <description>Detect the serum hs-CRP levels(ng/L), then analyze the correlation between the hs-CRP levels and COPD incidence.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The association between the pH value of EBC and COPD incidence.</measure>
    <time_frame>4 years</time_frame>
    <description>Detect the EBC pH value, then analyze the correlation between the EBC pH value and COPD incidence.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The association between serum miR-23a level and COPD incidence.</measure>
    <time_frame>4 years</time_frame>
    <description>Detect the serum miR-23a level, then analyze the correlation between serum miR-23a level and COPD incidence.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The association between incidence of COPD and other factors.</measure>
    <time_frame>4 years</time_frame>
    <description>The association between incidence of COPD and other factors (smoking habit, biomass exposure history, eating habit and incoming class).The incidence of COPD in the second and fourth year and the association between incidence of COPD and other factors (smoking habit(has or does not, if has: accumulative total smoking amount), biomass exposure history(yes or no), eating habit(light or greasy) and incoming class(family income per capita &gt;¥4500, or not)).</description>
  </secondary_outcome>
  <enrollment type="Anticipated">10000</enrollment>
  <condition>COPD</condition>
  <condition>FEV1</condition>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>No intervention</intervention_name>
    <description>This is a multi-center,observational, prospective, cohort study. A total of 10,000 subjects aged 40～75 without history of lung disease will be recruited and followed for 3 years. So there is no intervention in this study.</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        A total of 10,000 subjects aged 40～75 without history of lung disease will be recruited and
        followed for 3 years.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. aged at 40-75 years old;

          2. FEV1/FVC&gt;70% after inhaled bronchodilator

          3. have willing to participate in this study, follow the research program and have the
             ability to sign the informed consent;

          4. lived in a community for more than 1 years and has no plans to move out in the next 4
             years

          5. can be contacted

        Exclusion Criteria:

          1. history of asthma, COPD, lung cancer, active pulmonary tuberculosis, bronchiectasis,
             diffuse lung disease (interstitial pneumonia, pulmonary sarcoidosis, occupational lung
             disease, sarcoidosis et al) and pleural disease;

          2. history of lobectomy and / or lung transplantation;

          3. predicted life expectancy less than 3 years;

          4. history of severe psychiatric illnesses, mental disorders, neurological disorders,
             malignant tumors, chronic liver disease, heart failure, autoimmune diseases, chronic
             kidney disease;

          5. Alcoholism, drug abuse or abuse of toxic solvents;

          6. Cannot finish long term follow-up or poor compliance;

          7. Do not provide consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Guangfa Wang, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Peking University First Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Guangfa Wang, MD</last_name>
    <phone>+86 13810644029</phone>
    <email>wangguangfa@hotmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jiping Liao, MD</last_name>
    <phone>+86 13521714181</phone>
    <email>colorfulwing01@163.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Peking University First Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100034</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Guangfa Wang, MD</last_name>
      <phone>13810644029</phone>
      <email>wangguangfa@hotmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Jiping Liao, MD</last_name>
      <phone>13521714181</phone>
      <email>colorfulwing01@163.com</email>
    </contact_backup>
    <investigator>
      <last_name>Yunxia Wang, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Yijue Zhong, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Chao Sun, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The First Hospital of Qinhuangdao</name>
      <address>
        <city>Qinhuangdao</city>
        <state>Hebei</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hua Qiao, MD</last_name>
      <phone>13780358298</phone>
      <email>qh1202@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Second Hospital of Hebei Medical University</name>
      <address>
        <city>Shijiazhuang</city>
        <state>Hebei</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Xixin Yan, MD</last_name>
      <phone>15803210959</phone>
      <email>xi_xin_yan@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Henan Provincial People's Hospital</name>
      <address>
        <city>Zhengzhou</city>
        <state>Henan</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Limin Zhao, MD</last_name>
      <phone>18538297806</phone>
      <email>zlm9898@126.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Affiliated Hospital of Inner Mongolia Medical University</name>
      <address>
        <city>Hohhot</city>
        <state>Inner Mongolia</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xiuhua Fu, MD</last_name>
      <phone>13947142625</phone>
      <email>fuxiuhua555@sohu.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Second Hospital of Jilin University</name>
      <address>
        <city>Changchun</city>
        <state>Jilin</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jinzhi Yin, MD</last_name>
      <phone>13504409660</phone>
      <email>yjz6437@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Shandong Provincial Hospital Affiliated to Shandong University</name>
      <address>
        <city>Jinan</city>
        <state>Shandong</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Shujuan Jiang, MD</last_name>
      <phone>15168887199</phone>
      <email>shujuan-jiang@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Shanxi Medical University</name>
      <address>
        <city>Taiyuan</city>
        <state>Shanxi</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ruiying Wang, MD</last_name>
      <phone>13903436432</phone>
      <email>wry0526@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Xi'an Jiaotong University</name>
      <address>
        <city>Xi'an</city>
        <state>Shanxi</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Xiaomin Dang, MD</last_name>
      <phone>18991232795</phone>
      <email>dxming112@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Tianjin Medical University General Hospital</name>
      <address>
        <city>Tianjin</city>
        <state>Tianjin</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Lixia Dong, MD</last_name>
      <phone>13001385918</phone>
      <email>luckydonglixia@163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 29, 2018</study_first_submitted>
  <study_first_submitted_qc>May 21, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">May 22, 2018</study_first_posted>
  <last_update_submitted>May 21, 2018</last_update_submitted>
  <last_update_submitted_qc>May 21, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 22, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Peking University First Hospital</investigator_affiliation>
    <investigator_full_name>Guangfa Wang</investigator_full_name>
    <investigator_title>Head of Respiratory and critical Medicine, Principal Investigator, Clinical Professor</investigator_title>
  </responsible_party>
  <keyword>COPD incidence</keyword>
  <keyword>Decline in FEV1</keyword>
  <keyword>Inflammatory biomarkers</keyword>
  <keyword>EBC</keyword>
  <keyword>microRNA-23a</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

